Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2000 May;92(5):222–230.

Colorectal cancer: update on recent advances and their impact on screening protocols.

E N Briskey 1, R J Pamies 1
PMCID: PMC2640566  PMID: 10881471

Abstract

As the third leading cause of cancer cases and deaths in the United States, colorectal cancer has been an area of intense interest. The objectives of this article are, through a review of the literature published between 1995 to 1998, to examine current trends in the epidemiology of colorectal cancer, new information on genetic, dietary, and other risk factors; to evaluate the effectiveness of current screening guidelines for various populations; to review information on chemoprevention; and finally to examine new concepts on the horizon in the area of colorectal cancer research. Much of the recent research in the field has focused on etiology, dietary, and other risk factors. Many genetic factors have been discovered, which serve to elucidate the mechanism of pathogenesis of colorectal cancer as well as offer possible targets for treatment strategies. Dietary and risk factors for colorectal cancer may pave the way for chemoprevention. In light of the most recent information on colorectal cancer, one is able to more accurately assess current screening guidelines for their effectiveness in all populations based on epidemiologic data, as well as evaluate more novel screening strategies for their possible utility in the future. In addition to a review of the most up-to-date literature, the authors also provide their recommendations for screening based on the evidence in which the review of the literature provides. Finally, current and future treatment options are discussed. It is our hope that the physicians will find this review useful in the evaluation and care of patients at risk of developing colorectal cancer.

Full text

PDF
222

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvind P., Papavassiliou E. D., Tsioulias G. J., Qiao L., Lovelace C. I., Duceman B., Rigas B. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry. 1995 Apr 25;34(16):5604–5609. doi: 10.1021/bi00016a035. [DOI] [PubMed] [Google Scholar]
  2. Baron J. A., Sandler R. S., Haile R. W., Mandel J. S., Mott L. A., Greenberg E. R. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst. 1998 Jan 7;90(1):57–62. doi: 10.1093/jnci/90.1.57. [DOI] [PubMed] [Google Scholar]
  3. Bertino J. R. Chemotherapy of colorectal cancer: history and new themes. Semin Oncol. 1997 Oct;24(5 Suppl 18):S18–3-S18-7. [PubMed] [Google Scholar]
  4. Blum H. E. Colorectal cancer: future population screening for early colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369–1372. doi: 10.1016/0959-8049(95)00215-5. [DOI] [PubMed] [Google Scholar]
  5. Bond J. H. Fecal occult blood testing for colorectal cancer. Can we afford not to do this? Gastroenterol Clin North Am. 1997 Mar;26(1):57–70. doi: 10.1016/s0889-8553(05)70283-1. [DOI] [PubMed] [Google Scholar]
  6. Bostick R. M., Potter J. D., McKenzie D. R., Sellers T. A., Kushi L. H., Steinmetz K. A., Folsom A. R. Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study. Cancer Res. 1993 Sep 15;53(18):4230–4237. [PubMed] [Google Scholar]
  7. Breivik J., Lothe R. A., Meling G. I., Rognum T. O., Børresen-Dale A. L., Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997 Dec 19;74(6):664–669. doi: 10.1002/(sici)1097-0215(19971219)74:6<664::aid-ijc18>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  8. Byers T., Levin B., Rothenberger D., Dodd G. D., Smith R. A. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin. 1997 May-Jun;47(3):154–160. doi: 10.3322/canjclin.47.3.154. [DOI] [PubMed] [Google Scholar]
  9. Caan B. J., Coates A. O., Slattery M. L., Potter J. D., Quesenberry C. P., Jr, Edwards S. M. Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord. 1998 Feb;22(2):178–184. doi: 10.1038/sj.ijo.0800561. [DOI] [PubMed] [Google Scholar]
  10. Chattar-Cora D., Onime G. D., Coppa G. F., Valentine I. S., Rivera L. Anatomic, age, and sex distribution of colorectal cancer in a New York City Hispanic population. J Natl Med Assoc. 1998 Jan;90(1):19–24. [PMC free article] [PubMed] [Google Scholar]
  11. Clark J. W. Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. Semin Oncol. 1997 Oct;24(5 Suppl 18):S18–19-S18-24. [PubMed] [Google Scholar]
  12. Eddy D. M. Screening for colorectal cancer. Ann Intern Med. 1990 Sep 1;113(5):373–384. doi: 10.7326/0003-4819-113-5-373. [DOI] [PubMed] [Google Scholar]
  13. Fante R., Benatti P., di Gregorio C., De Pietri S., Pedroni M., Tamassia M. G., Percesepe A., Rossi G., Losi L., Roncucci L. Colorectal carcinoma in different age groups: a population-based investigation. Am J Gastroenterol. 1997 Sep;92(9):1505–1509. [PubMed] [Google Scholar]
  14. Gelfand D. W. Colorectal cancer. Screening strategies. Radiol Clin North Am. 1997 Mar;35(2):431–438. [PubMed] [Google Scholar]
  15. Giardiello F. M., Spannhake E. W., DuBois R. N., Hylind L. M., Robinson C. R., Hubbard W. C., Hamilton S. R., Yang V. W. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci. 1998 Feb;43(2):311–316. doi: 10.1023/a:1018898120673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Giovannucci E., Colditz G. A., Stampfer M. J., Hunter D., Rosner B. A., Willett W. C., Speizer F. E. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994 Feb 2;86(3):192–199. doi: 10.1093/jnci/86.3.192. [DOI] [PubMed] [Google Scholar]
  17. Glick S., Wagner J. L., Johnson C. D. Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer. AJR Am J Roentgenol. 1998 Mar;170(3):629–636. doi: 10.2214/ajr.170.3.9490943. [DOI] [PubMed] [Google Scholar]
  18. Goh H. S., Chan C. S., Khine K., Smith D. R. p53 and behaviour of colorectal cancer. Lancet. 1994 Jul 23;344(8917):233–234. doi: 10.1016/s0140-6736(94)93000-7. [DOI] [PubMed] [Google Scholar]
  19. Goldberg Y., Nassif I. I., Pittas A., Tsai L. L., Dynlacht B. D., Rigas B., Shiff S. J. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene. 1996 Feb 15;12(4):893–901. [PubMed] [Google Scholar]
  20. Gore R. M. Colorectal cancer. Clinical and pathologic features. Radiol Clin North Am. 1997 Mar;35(2):403–429. [PubMed] [Google Scholar]
  21. Hoops T. C., Traber P. G. Molecular pathogenesis of colorectal cancer. Hematol Oncol Clin North Am. 1997 Aug;11(4):609–633. doi: 10.1016/s0889-8588(05)70453-6. [DOI] [PubMed] [Google Scholar]
  22. Johnson H., Jr, Carstens R. Anatomical distribution of colonic carcinomas. Interracial differences in a community hospital population. Cancer. 1986 Aug 15;58(4):997–1000. doi: 10.1002/1097-0142(19860815)58:4<997::aid-cncr2820580435>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  23. Kahn M. J., Morrison D. G. Chemoprevention for colorectal carcinoma. Hematol Oncol Clin North Am. 1997 Aug;11(4):779–794. doi: 10.1016/s0889-8588(05)70460-3. [DOI] [PubMed] [Google Scholar]
  24. Kroser J. A., Bachwich D. R., Lichtenstein G. R. Risk factors for the development of colorectal carcinoma and their modification. Hematol Oncol Clin North Am. 1997 Aug;11(4):547–577. doi: 10.1016/s0889-8588(05)70451-2. [DOI] [PubMed] [Google Scholar]
  25. Kune G. A., Kune S., Watson L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988 Aug 1;48(15):4399–4404. [PubMed] [Google Scholar]
  26. La Vecchia C., Braga C., Negri E., Franceschi S., Russo A., Conti E., Falcini F., Giacosa A., Montella M., Decarli A. Intake of selected micronutrients and risk of colorectal cancer. Int J Cancer. 1997 Nov 14;73(4):525–530. doi: 10.1002/(sici)1097-0215(19971114)73:4<525::aid-ijc12>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  27. Labianca R., Pessi M. A., Zamparelli G. Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. Drugs. 1997 Apr;53(4):593–607. doi: 10.2165/00003495-199753040-00005. [DOI] [PubMed] [Google Scholar]
  28. Levin B., Hess K., Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997 May 12;157(9):970–976. [PubMed] [Google Scholar]
  29. Lieberman D. Endoscopic screening for colorectal cancer. Gastroenterol Clin North Am. 1997 Mar;26(1):71–83. doi: 10.1016/s0889-8553(05)70284-3. [DOI] [PubMed] [Google Scholar]
  30. Mandel J. S. Colorectal cancer screening. Cancer Metastasis Rev. 1997 Sep-Dec;16(3-4):263–279. doi: 10.1023/a:1005848110521. [DOI] [PubMed] [Google Scholar]
  31. Maxwell-Armstrong C. A., Durrant L. G., Scholefield J. H. Colorectal cancer vaccines. Br J Surg. 1998 Feb;85(2):149–154. doi: 10.1046/j.1365-2168.1998.00704.x. [DOI] [PubMed] [Google Scholar]
  32. Nakayama T., Watanabe M., Teramoto T., Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997 Dec;66(4):238–243. doi: 10.1002/(sici)1096-9098(199712)66:4<238::aid-jso3>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  33. O'Reilly S., Rowinsky E. K. Experimental chemotherapeutic agents for the treatment of colorectal carcinoma. Hematol Oncol Clin North Am. 1997 Aug;11(4):721–758. doi: 10.1016/s0889-8588(05)70458-5. [DOI] [PubMed] [Google Scholar]
  34. Ogunbiyi O. A., Goodfellow P. J., Herfarth K., Gagliardi G., Swanson P. E., Birnbaum E. H., Read T. E., Fleshman J. W., Kodner I. J., Moley J. F. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol. 1998 Feb;16(2):427–433. doi: 10.1200/JCO.1998.16.2.427. [DOI] [PubMed] [Google Scholar]
  35. Qiao L., Hanif R., Sphicas E., Shiff S. J., Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol. 1998 Jan 1;55(1):53–64. doi: 10.1016/s0006-2952(97)00400-0. [DOI] [PubMed] [Google Scholar]
  36. Qiao L., Shiff S. J., Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett. 1997 May 19;115(2):229–234. doi: 10.1016/s0304-3835(97)04740-x. [DOI] [PubMed] [Google Scholar]
  37. Sandler R. S., Galanko J. C., Murray S. C., Helm J. F., Woosley J. T. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998 Mar;114(3):441–447. doi: 10.1016/s0016-5085(98)70526-8. [DOI] [PubMed] [Google Scholar]
  38. Shiff S. J., Koutsos M. I., Qiao L., Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res. 1996 Jan 10;222(1):179–188. doi: 10.1006/excr.1996.0023. [DOI] [PubMed] [Google Scholar]
  39. Shiff S. J., Qiao L., Tsai L. L., Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995 Jul;96(1):491–503. doi: 10.1172/JCI118060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Shiff S. J., Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology. 1997 Dec;113(6):1992–1998. doi: 10.1016/s0016-5085(97)99999-6. [DOI] [PubMed] [Google Scholar]
  41. Stone W. L., Papas A. M. Tocopherols and the etiology of colon cancer. J Natl Cancer Inst. 1997 Jul 16;89(14):1006–1014. doi: 10.1093/jnci/89.14.1006. [DOI] [PubMed] [Google Scholar]
  42. Stürmer T., Glynn R. J., Lee I. M., Manson J. E., Buring J. E., Hennekens C. H. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998 May 1;128(9):713–720. doi: 10.7326/0003-4819-128-9-199805010-00003. [DOI] [PubMed] [Google Scholar]
  43. Thomas C. R., Jr, Jarosz R., Evans N. Racial differences in the anatomical distribution of colon cancer. Arch Surg. 1992 Oct;127(10):1241–1245. doi: 10.1001/archsurg.1992.01420100107018. [DOI] [PubMed] [Google Scholar]
  44. Tominaga O., Nita M. E., Nagawa H., Muto T. Screening for APC mutations based on detection of truncated APC proteins. Dig Dis Sci. 1998 Feb;43(2):306–310. doi: 10.1023/a:1018846103834. [DOI] [PubMed] [Google Scholar]
  45. Yokoyama S., Shatney C. H., Mochizuki H., Hase K., Johnson D. L., Cummings S., Trollope M. L., Tamakuma S. The potential role of fecal carbonic anhydrase II in screening for colorectal cancer. Am Surg. 1997 Mar;63(3):243–247. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES